Drugs / KN3835
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07846280 | Oct 2026 → Dec 2028 expected | toe, misshapen | Endo USA Inc., a Keenova Therapeutics Company | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07759362 | Aug 2026 → Dec 2027 expected | toe, misshapen | Endo USA Inc., a Keenova Therapeutics Company | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KN3835 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07846280 ↗ |